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Abstract
Background: Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in the inhibition and
elimination of malignant tumor cells. To investigate the immunoregulatory role of NK cells and their potential as diagnostic
markers, NK cell activity (NKA) was analyzed in prostate cancer (PCa) patients with particular focus on NK cell subset
distribution.
Methods: Prospective data of NKA and NK cell subset distribution patterns were measured from 51 patients initially
diagnosed with PCa and 54 healthy controls. NKA was represented by IFN-c levels after stimulation of the peripheral blood
with PromocaH. To determine the distribution of NK cell subsets, PBMCs were stained with fluorochrome-conjugated
monoclonal antibodies. Then, CD16+CD56dim and CD162CD56bright cells gated on CD56+CD32 cells were analyzed using a
flow-cytometer.
Results: NKA and the proportion of CD56bright cells were significantly lower in PCa patients compared to controls (430.9 pg/
ml vs. 975.2 pg/ml and 2.3% vs. 3.8%, respectively; p,0.001). Both tended to gradually decrease according to cancer stage
progression (p for trend = 0.001). A significantly higher CD56dim-to-CD56bright cell ratio was observed in PCa patients (41.8 vs.
30.3; p,0.001) along with a gradual increase according to cancer stage progression (p for trend = 0.001), implying a
significant reduction of CD56bright cells in relation to the alteration of CD56dim cells. The sensitivity and the specificity of NKA
regarding PCa detection were 72% and 74%, respectively (best cut-off value at 530.9 pg/ml, AUC= 0.786).
Conclusions: Reduction of CD56bright cells may precede NK cell dysfunction, leading to impaired cytotoxicity against PCa
cells. These observations may explain one of the mechanisms behind NK cell dysfunction observed in PCa
microenvironment and lend support to the development of future cancer immunotherapeutic strategies.
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Introduction
Natural killer (NK) cells serve a major role in the innate and
adaptive immune responses against tumor transformation or
pathogen-infected cells [1]. NK cells exert natural cytotoxicity to
eliminate malignant cells without prior sensitization or class I
MHC restriction [1,2]. Furthermore, NK cells stimulate the
adaptive immune response by secreting proinflammatory cytokines
to counteract the escape mechanisms promoted by tumor cells [3].
Progress has been made in understanding the biology of NK cells;
nonetheless, further clarification remains regarding anti-tumor
effects of NK cell activity (NKA) and patterns of subset distribution
in PCa.
NK cells are defined phenotypically by their expression of
CD56 and lack of CD3 expression [4]. According to membrane
densities of CD56 and CD16, NK cells are classified into
CD16+CD56dim and CD162CD56bright subsets [5]. The majority
are CD56dim cells that mainly exert potent cytotoxicity [6]. In
contrast, CD56bright cells mediate low cytotoxicity but acquire
greater cytolytic activity than CD56dim cells upon activation due to
release of proinflammatory cytokines such as IFN-c [7]. The level
of IFN-c, i.e., NKA, is generally associated with oncological
prognosis, which implies the essential role of differential NK cell
subset expression in the immune regulation of tumor cells [8].
NKA has shown to serve an important role in surveillance and in
the elimination of tumor cells [9]. Studies have shown that low
NKA leads to high levels of tumor occurrence and metastasis, and
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that its degree correlates with invasiveness of malignancy [10]. On
the contrary, high NKA has been shown to correlate with lower
incidence of tumors, and their infiltration in certain tumors, i.e.,
melanoma, head and neck squamous cell carcinomas, is an
indicator for a better oncological outcome [11,12].
There is accumulating evidence that an impaired immune
response is a crucial factor in the pathogenesis of prostate cancer
(PCa) [13,14]. NK cell dysfunction has been implicated in PCa
along with a variety of tumors [15,16]. Despite several proposed
mechanisms including reduced number, immunosuppressive
cytokines, and receptor repertoire imbalance, the pathophysiology
of NK cell dysfunction in PCa is not fully understood [5].
Regarding the role of NKA in tumor suppression, harnessing the
mechanisms of NK cells could clearly be an important component
for successful immunotherapy against PCa. Prostate-specific
antigen (PSA) is the most widely used serum marker that has
revolutionized the early detection and management of PCa.
However, the relative lack of cancer-specificity and lack of an
upper or lower threshold value are major drawbacks.
To address these issues, NKA and the distributions of CD56dim
and CD56bright subsets were analyzed between PCa patients and
controls. Our findings indicate that immunoregulation in PCa is
impaired due to a reduction in NKA preceded by redistribution of
NK cell subsets. Moreover, evaluation of the diagnostic perfor-
mance of NKA revealed that it may be applied as a supportive
marker in addition to PSA.
Materials and Methods
1. Patients and Controls
This prospective cross-sectional analysis involved 51 patients
with newly diagnosed biopsy-proven PCa due to a PSA elevation
noted on health examinations from March to December, 2012. 54
age-matched controls were self-volunteered healthy individuals
whose prostate volume, PSA, and DRE were within normal
accepted ranges. None of the patients had received prior treatment
for PCa, were known to have immunological or other malignant
conditions, and were all free of active infection or inflammation as
assessed by white blood cell count,10,000 cells/ml and C-reactive
protein ,1.0 mg/L (Table 1). All controls were free from
inflammatory conditions without prior exposure to immunosup-
pressive agents. Independent approval was obtained from Yonsei
University Ethics Committee (4-2011-0660), with all blood
samples collected after obtaining informed consent prior to radical
prostatectomy. All participants provided written consent to
participate in the current study.
2. NK Cell Activity
Cytotoxic activity of NK cells was determined using the NK
Vue-KitH (ATgen, Sungnam, Korea). Whole blood was collected
using BD VacutainerH heparinN1 tubes. 1 ml of whole blood was
incubated for 24 hrs, at 37uC, under 5% CO2 with indicated dose
of PromocaH and 1 ml of RPMI 1640 media. Cell-free superna-
tants were harvested, and IFN-c levels were determined according
to manufacturer’s protocols.
3. NK Cell Subset Distribution
3.1. Preparation of PBMCs. 3 ml of heparinized venous
blood was obtained and analyzed within 4 h of collection. PBMCs
were isolated by density gradient centrifugation using CPTH cell
preparation tubes (BD VacutainerH) at 1600 g for 20 min at 20uC.
The collected PBMCs (1226106 cells/ml) were washed and
resuspended in 5% fetal bovine serum (FBS)+phosphate buffered
saline (PBS).
3.2. Antibody staining. For the expression of CD3, CD16,
and CD56 on NK cells, PBMCs were stained with Alexa-anti-
CD3, PE-anti-CD16, and FITC-anti-CD56 fluorochrome-conju-
gated monoclonal antibodies (BD Biosciences). After staining for
30 min at 4uC, cells were washed extensively and fixed in 1%
paraformaldehyde-PBS until assessment.
3.3. Flow cytometry. To determine the total percentage of
NK cells gated in the CD32CD56+ cell population, at least 10,000
target cells were acquired by LSRII flow-cytometry (BD Biosci-
ences). The distribution of CD16+CD56dim NK cells and
CD162CD56bright NK cells gated from the CD32CD56+ cell
population is presented as the percentage of total NK cells. For
each sample, the data were further analyzed by FlowJo 8.1.1.1
(Tree Star, Inc., Ashland, OR, USA).
4. Cancer Stage Classification
PCa staging was determined according to the 7th American
Joint Committee on Cancer (AJCC) TNM system. Stage
distribution and pathological characteristics are shown in
Table 2. Pathology was confirmed by a single pathologist.
5. Statistical Analysis
Statistical analyses were performed using Mann-Whitney U
tests when comparing unpaired two-group data and Kruskal-
Wallis tests with Bonferroni post-hoc correction when comparing
more than two groups. The accuracy of NKA and the CD56dim-
Table 1. Demographic data of clinicopathological
characteristics of PCa patients and controls.
Patients Controls p-value
Clinical characteristics
n 51 54 NS
Age (years) 63.760.98 61.660.78 0.092
BMI 24.460.44 24.160.35 0.705
Preoperative PSA (ng/ml) 16.963.5 1.160.15 ,0.001
Prostate volume (gm) 34.261.6 28.861.8 0.02
WBC (cells/ml) 64636236 62786228 0.874
% Lymphocyte 31.461.1 33.260.9 0.153
% Neutrophil 57.961.4 55.661.3 0.269
C-reactive protein ,1.0 ,1.0 NS
Tumor characteristics
ECE 27 (53%) NS
SV invasion 9 (16%) NS
LN metastasis 8 (15%) NS
TNM stage NS
II 18 (36%)
III 24 (47%)
IV 9 (17%)
Pathologic Gleason score NS
6 10 (19%)
7 25 (49%)
8 8 (17%)
9 8 (15%)
All values are given as means 6 SE.
NS = not significant; ECE = extracapsular extension; SV = seminal vesicle;
LN = lymph node.
doi:10.1371/journal.pone.0078049.t001
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to-CD56bright ratio in detecting PCa was determined by receiver
operating characteristics-derived area under the curve (AUC).
Correlation analysis was used to evaluate associations among
NKA, CD56dim-to-CD56bright ratio, and clinicopathological var-
iables. Statistical analyses were performed using SPSS (v.18.0).
Results
1. Demographic Data
All patients and controls were clinically and pathologically
investigated with respect to factors shown in Table 1. Factors that
may influence one’s immune status manifested no differences
between groups.
2. Frequency of NK Cells and Distribution of CD56dim and
CD56bright NK Cell Subsets
Representative flow cytometric data shows the distribution of
total NK cell population represented as CD32CD56+ cells
(Fig. 1A) and two major subsets, CD16+CD56dim and
CD162CD56bright, expressed as a percentage of total NK cells
(Fig. 1B). Total NK circulating frequencies did not differ between
patients and controls or between cancer stage groups (Fig. 2A;
Table 2). However, a preferential decrease in frequency of
CD56bright cells was noted in patients. Moreover, CD56bright cells
tended to gradually decrease according to cancer stage progres-
sion, i.e., extracapsular extension, LN or adjacent organ metastasis
(Fig. 2B; Table 2). A significantly higher CD56dim-to-CD56bright
NK cell ratio was observed in patients compared to controls, with
a tendency to increase according to stage progression (p for
trend= 0.001) (Table 2).
3. NK Cell Activity
Results obtained are presented in Fig. 3 and Table 2. As
indicated, patients showed significantly lower NKA. According to
stage progression, those with higher stages showed a greater
reduction of NKA (p for trend ,0.001).
Table 2. Comparisons of NK cell activity, % total NK cell population, distribution of CD56dim and CD56bright subsets, and the
CD56dim-to-CD56bright ratio between patients and controls.
Patients Controls p
Total Stage II Stage III Stage IV
NK cell activity (pg/ml) 430.9667.1 546.16136.8 427.8687.9 194.5673.8 975.2685.7 ,0.001
NK cell population
cells/ml 386561944 355261351 361561462 419461762 466261826 0.312
%{ 20.261.6 16.961.8 21.861.9 23.965.8 21.861.7 0.595
CD56dim subset
cells/ml 325861837 29596935 302361659 377461769 429861134 0.208
%` 85.3661.2 83.561.8 86.261.9 88.163.2 88.960.8 0.103
CD56bright subset
cells/ml 96.5661.3 94.2630.3 77.5640.8 84.5619.3 202.5690.1 ,0.001
%` 2.360.2 2.760.3 2.260.2 1.760.4 3.860.3 ,0.001
CD56dim-to-CD56bright ratio 41.862.3 35.863.3 43.663.3 54.467.4 30.363.1 ,0.001
{Expressed as a percentage of total PBMCs.
`Expressed as a percentage of total NK cells.
Patients were further grouped according to cancer stage. All data represented as mean 6 SE.
doi:10.1371/journal.pone.0078049.t002
Figure 1. (A) Representative flow cytometric data of the
distribution of total NK cell population represented by
CD32CD56+ cells. (B) Representative flow cytometric data of two
major NK cell subsets detected in peripheral blood. Left, upper box:
CD16+CD56dim NK cell subset. Right, lower box: CD162CD56bright NK
cell subset.
doi:10.1371/journal.pone.0078049.g001
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4. Analysis by ROC Curves
ROC curves and best cut-off values were used to calculate the
sensitivity and specificity of NK cell-related parameters (Table 3).
The sensitivity and specificity of NKA with respect to PCa
detection were 72% and 74%, respectively, whereas the CD56dim-
to-CD56bright cell ratio showed a sensitivity of 66% and a
specificity of 71% (Fig. 4A). In further analysis, the sensitivity
and specificity of NKA were determined according to two PSA
values grouped as 4 to 10 ng/ml, which is the diagnostic grey-
zone, and levels greater than 10 ng/ml. At a set specificity of 74%,
NKA for PSA values within the grey-zone showed higher
sensitivity (73% vs. 70%) and AUC (0.8260.06 vs. 0.7660.07)
relative to PSA values greater than 10 ng/ml (Fig. 4B).
5. NK Cell Activity and CD56dim-to-CD56bright Cell Ratio
According to Clinicopathological Variables
NKA showed negative correlations with PSA, cancer stage, and
the CD56dim-to-CD56bright ratio. On the other hand, CD56dim-to-
CD56bright cell ratio showed positive correlations with PSA and
cancer stage (Table 4). NKA and CD56dim-to-CD56bright ratio was
compared between controls and patients grouped according to
clinicopathological variables (Table 5). Although CD56dim-to-
CD56bright ratio failed to discriminate patients with Gleason scores
,7 and those without extracapsular extension from controls, all
other subgroups were distinguishable from controls by NKA and
CD56dim-to-CD56bright ratio. Analysis in-between patient sub-
groups revealed significantly higher CD56dim-to-CD56bright ratio
in patients with pathologically confirmed LN metastasis (p = 0.043;
data not shown).
Discussion
The aim of the present study was to clarify the role of NK cells
in the immune response against PCa. Several mechanisms of PCa
development and progression have been proposed, including
hormonal, metabolic alterations, and immune response [6,17].
There is accumulating evidence that different lymphocyte
populations are involved in cell-mediated immunosuppression
that leads to occurrence and progression of PCa [13,18,19].
However, there is limited information regarding the functional
role of NK cells in the immune response to PCa. To address this
issue, we investigated NKA as a marker for IFN-c levels and the
distribution of NK cell subsets in PCa patients. The results of our
study indicate that impaired NKA is presumably preceded by a
reduction in CD56bright cells, and that the level of NKA could be
utilized as a supportive diagnostic marker for PSA.
1. Preferential Reduction of CD56bright NK Cells in PCa
Patients
NK cells are functionally classified into CD56dim and CD56bright
subsets. CD16+CD56dim cells are effector cells with high quantities
of cytolytic granules that express potent cytotoxicity against tumor
cells [4]. CD162CD56bright cells release proinflammatory cyto-
kines such as IFN-c which drives inflammatory mechanisms that
regulate tumor initiation, immunoevasion, survival, and outgrowth
[20,21]. Recent discoveries have revealed that CD56bright cells
constitute the majority of NK cells in lymphoid tissues and that
they are not just a minor subpopulation among NK cells but are
immature precursors of CD56dim cells [22]. This work focuses on
this particular subset, regarding its importance in the regulation of
NK cell-mediated response against tumor cells.
Figure 2. (A) Boxplot diagrams showing flow cytometric
distribution results of total NK cell population % between
controls and patients, grouped according to cancer stage. No
significant differences of total NK population were noted between
patients and controls, and within stage groups. (B) Boxplot diagrams
showing flow cytometric distribution results of CD56dim and CD56bright
subset distributions within total NK cells between controls and patients,
grouped according to cancer stage. *p,0.05, **p,0.01 in relation to
controls.
doi:10.1371/journal.pone.0078049.g002
Figure 3. Boxplot diagram comparing NK cell activity between
controls and patients grouped according to cancer stage.
**p,0.01 in relation to controls.
doi:10.1371/journal.pone.0078049.g003
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Investigation on distributional patterns of NK cell subsets
revealed a significant decrease of CD56bright cells without
alteration of CD56dim cells. Previous studies on various tumor-
bearing hosts have reported rather distinct interrelationships
between CD56dim and CD56bright subsets. In contrast to our
results, a reduction in CD56dim cells without alteration of
CD56bright cells was noted in gastric and esophageal cancers
[23]. On the other hand, a reduction in CD56bright cells was
observed in breast, head and neck cancers, and an equal
distribution of CD56dim cells in PCa; results that are consistent
with the present study [7,17].
2. Alteration of CD56bright NK Cells as a Response
Mechanism to Tumor Microenvironment
Our study primarily observed a preferential reduction of
CD56bright cells without alteration of CD56dim cells. Although
the underlying cause has not yet been clearly defined, two possible
explanations can be raised; maturation process and recruitment
process.
As mentioned, CD56bright cells are accepted as precursors to
CD56dim cells, with each subset representing a distinct maturation
stage [24]. Possibly, an excessive demand for effector cells in
response to tumor may have provoked a transition of immature
CD56bright cells into CD56dim cells. A similar explanation has been
proposed for the reduction of CD56bright cells in patients with head
and neck cancers [7]. However, this presupposes a concomitant
increase of CD56dim cells, which was not observed in the present
study.
An alternative explanation without demonstration is that
peripheral CD56bright cells may have been recruited to lymphoid
tissue sites as metastatic LNs to acquire cytotoxicity. This idea was
based on previous observations that CD56bright cells preferentially
accumulate in the T cell area of LNs until being activated to
produce proinflammatory cytokines [7,22,22]. Moreover, the
observation that CD56bright cells isolated from human LNs
become strongly cytotoxic upon stimulation by IL-2 suggests that
NK cells recruited to LNs might represent an immature pool of
effector cells [25]. A significantly higher CD56dim-to-CD56bright
cell ratio in patients with pathologically confirmed LN metastasis
was observed in our study, implying that these circulating cells
may have been recruited to pathologic or secondary LNs in
response to tumor. This is of relevance because LNs are usually the
primary metastatic sites and CD56bright cells are the primary
subset found in LNs that counteract the metastatic cells [26]. To
confirm this issue, it would be interesting to examine whether
CD56bright cells are accumulated in metastatic LNs following LN
dissection.
3. NK Cell Dysfunction as a Consequence of Reduction of
CD56bright NK Cells
NKA was investigated to determine the influence of reduction
of CD56bright cells on cytolytic activity against tumor cells. Parallel
to observations with CD56bright cells, NKA was observed to be
lower in PCa patients, along with a tendency to gradually decrease
according to cancer stage progression. These findings are
consistent with previous reports that showed NKA is compromised
in a broad spectrum of hematological and solid tumors [8,10,27].
Several mechanisms of compromised NKA have been proposed,
such as decreased number of tumor-infiltrating NK cells [23],
increased surface receptors for immune suppressor factors [28],
and inactivation of effector cells [10].
Correlations observed between NKA and CD56dim-to-
CD56bright cell ratio may be of direct relevance to suggest an
additional mechanism that weak NKA is a consequence of
reduced CD56bright cells. CD56bright cells are known to be major
sources for IFN-c [22], as observed in in vitro studies where
CD56bright cells were shown to preferentially proliferate in co-
culture with immature dendritic cells and lipopolysaccharides to
produce IFN-c [29]. Also, stimulation of CD56bright cells with
transduced carcinoma cells resulted in an enhanced ability to
produce IFN-c and impart high cytotoxicity [6]. Further, in vivo
studies have shown that tonsillar CD56bright cells produce IFN-c
before maturation into effector cells [25]. Conversely, a reduction
of CD56bright cells was observed to induce impaired secretion of
IFN-c in patients with allergic rhinitis [30]. Considering these
supportive findings that secretion of IFN-c directly depends on
CD56bright cells, we suggest that the reduction of CD56bright cells is
a potential mechanism involved in low NKA, which leads to
impaired cytotoxicity against PCa cells.
4. NK Cell Activity, a Supportive Diagnostic Marker for
PSA
ROC curves revealed that NKA may serve as a supportive
marker for PSA in diagnosing PCa. Although it is clear that PSA
provides the highest diagnostic value for PCa, a major limitation is
its lack of cancer-specificity which causes unnecessary risks and
costs, especially in the diagnostic grey-zone [31]. Although
ongoing challenges strive to develop novel methods of PCa
detection, none have clearly outweighed the benefits against
drawbacks [14]. This investigation raises the possibility that NKA
Figure 4. (A) ROC curves comparing the performances of NK cell activity and CD56dim-to-CD56bright ratio measurements. (AUC=Area
Under the Curve). (B) ROC curves comparing the performances of NK cell activity measurement according to PSA grouped as; 4 to 10 ng/ml and
greater than 10 ng/ml. (AUC=Area Under the Curve).
doi:10.1371/journal.pone.0078049.g004
Table 3. Comparisons of sensitivity and specificity of NK cell activity and CD56dim-to-CD56bright ratio to detect PCa.
Diagnostic test AUC Sensitivity (95% CI) Specificity (95% CI) Cut-off value
NK cell activity 0.7960.05 72% 74% 530.9 pg/ml
PSA 4–10 ng/ml 0.8260.06 73% 74%
PSA .10 ng/ml 0.7660.07 70% 74%
CD56dim-to-CD56bright ratio 0.7260.06 66% 71% 35.5
AUC= area under the curve.
The sensitivity of NK cell activity for corresponding PSA range is set at 74% specificity.
doi:10.1371/journal.pone.0078049.t003
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may be utilized in combination with PSA to provide additional
diagnostic value, especially for those within the diagnostic grey-
zone.
This study was based on controls versus patients diagnosed with
PCa due to elevated PSA on a routine health examination.
Therefore, the absence of PCa patients with normal PSA (,4 ng/
ml) was the major limitation of this study, which hampered a direct
comparison of diagnostic yield between PSA and NKA. An
extended population study is needed to confirm our preliminary
findings and to assess cost-effectiveness.
Conclusions
This observational study provided novel findings that
CD56bright cells serve an important role in adaptive response
against PCa cells. This notion lends further support that
longitudinal studies regarding NK cell immunosurveillance clearly
deserve additional research to potentially lead to novel immuno-
therapeutic strategies for enhancing oncological outcomes of PCa.
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